Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006732 · ClinicalTrials.gov registry record · Phase 3
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 809
- Enrollment target
- 20
- Study locations
NCT02006732 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 809 participants, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02006732, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 809 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tiotropium
- DRUG olodaterol
Study Locations (20)
South Carolina
- 1237.26.10607 Boehringer Ingelheim Investigational Site - Gaffney
- 1237.26.10617 Boehringer Ingelheim Investigational Site - Greenville
- 1237.26.10608 Boehringer Ingelheim Investigational Site - Spartanburg
- 1237.26.10604 Boehringer Ingelheim Investigational Site - Union
Ohio
- 1237.26.10603 Boehringer Ingelheim Investigational Site - Columbus
- 1237.26.10621 Boehringer Ingelheim Investigational Site - Dayton
- 1237.26.10612 Boehringer Ingelheim Investigational Site - Toledo
Florida
- 1237.26.10619 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.26.10614 Boehringer Ingelheim Investigational Site - Tampa
Texas
- 1237.26.10609 Boehringer Ingelheim Investigational Site - Boerne
- 1237.26.10602 Boehringer Ingelheim Investigational Site - San Antonio
Alabama
- 1237.26.10620 Boehringer Ingelheim Investigational Site - Jasper
Connecticut
- 1237.26.10618 Boehringer Ingelheim Investigational Site - Stamford
Georgia
- 1237.26.10616 Boehringer Ingelheim Investigational Site - Duluth
Missouri
- 1237.26.10613 Boehringer Ingelheim Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006732
The ClinicalTrials.gov registry entry for NCT02006732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 809 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (22% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02006732 reports 20 study locations spanning 13 distinct geographic areas - top geographies include South Carolina, Ohio, Florida.
Frequently Asked Questions
What is clinical trial NCT02006732 about?
NCT02006732 is a clinical study titled "Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)". The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.
What is the current status of trial NCT02006732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 809 participants. The study started on 2013-11. Estimated completion is 2014-11.
What conditions does trial NCT02006732 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT02006732?
The interventions under investigation include: placebo (DRUG), tiotropium (DRUG), olodaterol (DRUG).
Who is sponsoring clinical trial NCT02006732?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006732 being conducted?
This trial has 20 study locations across Alabama, Connecticut, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.